Objective Pharmacogenomics is an emerging discipline with a great potential for improving future clinical care. The linkage between the knowledge of treatment outcome and the underlying molecular alteration constitutes the principle of pharmacogenomics. The recent d evelopments of Herceptin (targeting the HER2 oncoprotein in breast cancer) and Glivec (targeting the BCR-ABL translocation in leukaemia) have demonstrated a close relationship between the molecular alteration and the clinical response. The success of these treatments has depended absolutely upon the development of appropriate clinical diagnostic tests (pharmacodiagnostics) to identify those patients, who are most likely to benefit from the treatment. The main objective of the proposed industry-academia part nership is to develop newpharmacodiagnostics to improve the selection of patients for targeted cancer therapies. DakoCytomation is a company at the forefront of the development of pharmacodiagnostics as evidenced by their strong involvement in ER and HER2. Dr. Bartlett research group at Glasgow University has achieved a unique expert position by combining translational research with histopathological evaluation of novel targeted cancer therapies tested by the pharmaceutical industry in European clinical tri als. Through exchange of experienced researchers, it is the intention to extend substantially the existing collaboration between DakoCytomation and Dr. Bartlett research group. This efficient way of combining complementary skills makes the objective very r ealistic. The new pharmacodiagnostic assays will be based on a) combining and optimising existing detection principles, b) combining detection of existing and/or novel markers on the same specimens and c) identifying new diseases/therapy indications for ex isting and optimised assays. Fields of science natural sciencesbiological sciencescell biologycell signalingnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologyleukemianatural sciencesbiological scienceshistology Programme(s) FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006 Topic(s) MOBILITY-1.3 - Marie Curie Host Fellowships - Transfer of knowledge (TOK) Call for proposal FP6-2002-MOBILITY-3 See other projects for this call Funding Scheme TOK - Marie Curie actions-Transfer of Knowledge Coordinator DAKOCYTOMATION DENMARK A/S EU contribution No data Address Produktionsvej, 42 GLOSTRUP Denmark See on map Total cost No data Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all UNIVERSITY OF GLASGOW. United Kingdom EU contribution No data Address University Avenue GLASGOW See on map Total cost No data
